This recent work further indicated that Sox4 is a key oncogenic target and critical mediator of C/EBPα mutants in acute myeloid leukemia (AML), suggesting a potential novel therapeutic approach to the treatment of this disease.26, 27 However, the clinical implications of SOX4 expression and its role of AML leukemogenesis are not well understood. This evidence concerns the gene CEBPA and acute myeloid leukemia.